Researchers looked at the 250 drugs with the greatest Medicare Part D spending in 2016, and found 46 percent of them did not have a cost-effectiveness analysis. Those 115 drugs with absent cost-effectiveness analyses represent 33 percent of all Medicare Part D spending.
For the 135 drugs with available cost-effectiveness analyses, many of the studies failed to meet minimum quality standards, according to the report.
Ninety-one of the drugs included in the study had a generic equivalent, and 159 had some exclusivity.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
